Sunitinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Sunitinib: From Renal Cell Carcinoma to Liposarcoma
One-Sentence Summary
Sunitinib is a multitargeted tyrosine kinase inhibitor whose established, mechanistically-founded indication is renal cell carcinoma (confirmed within this evidence pack via its role as a direct comparator/standard-of-care arm across the RCC trial set). The TxGNN model predicts it may also be effective for Liposarcoma, with 3 clinical trials and 9 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Renal Cell Carcinoma (inferred from evidence-pack rationale for the RCC prediction, which states this reflects sunitinib's originally approved MOA, not a repurposing hypothesis; formal TFDA label text is a blocking data gap, DG001) |
| Predicted New Indication | Liposarcoma |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L2 |
| New Zealand Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002 — DrugBank MOA lookup pending). Based on the information available in this evidence pack, sunitinib is a multitargeted receptor tyrosine kinase inhibitor (VEGFR1-3, PDGFR-α/β, KIT, RET), and its efficacy in renal cell carcinoma — which is highly dependent on VEGF-driven tumor angiogenesis — is well established; this is corroborated by dozens of RCC trials in the evidence pack where sunitinib serves as the active comparator/standard-of-care arm (see Rank 9: "renal carcinoma").
Liposarcoma, particularly the dedifferentiated and myxoid/round-cell subtypes, frequently shows activated PDGFR-β signaling and angiogenesis dependence — mechanistically within reach of sunitinib's anti-VEGFR/PDGFR activity. Two Phase 2 sarcoma trials in the evidence pack (NCT00400569, n=48; NCT00474994, n=53) directly tested sunitinib in metastatic/unresectable soft-tissue sarcoma populations that included liposarcoma, and case-level literature reports durable clinical benefit in heavily pretreated metastatic liposarcoma. However, response rates vary substantially by histological subtype, and no liposarcoma-specific randomized trial has been completed, which is why the evidence level remains L2 with a "Research Question" recommendation rather than a stronger decision.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00400569 | Phase 2 | Completed | 48 | Open-label Phase II trial of sunitinib malate in adult patients with metastatic/unresectable soft-tissue sarcoma, including liposarcoma, leiomyosarcoma, fibrosarcoma, and MFH |
| NCT00474994 | Phase 2 | Completed | 53 | Multicenter continuous-dosing sunitinib trial in non-GIST sarcomas, covering liposarcoma subtypes |
| NCT02048371 | Phase 2 | Completed | 131 | SARC024: primarily evaluated regorafenib (not sunitinib) across sarcoma subtypes; only indirectly relevant as precedent for TKI activity in soft-tissue sarcoma |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21154746 | 2011 | Phase 2 (non-RCT) | International Journal of Cancer | Phase II study of sunitinib malate in relapsed/refractory soft-tissue sarcoma, focused on leiomyosarcoma, liposarcoma, and MFH |
| 23482782 | 2013 | Case report | Anticancer Research | Long-lasting clinical benefit of sunitinib in a heavily pretreated metastatic liposarcoma case |
| 38254762 | 2024 | Review/Genomic | Cancers | Genetic, epigenetic, and transcriptomic alterations in liposarcoma relevant to target-therapy selection |
| 22987955 | 2012 | Review | Annals of Oncology | Histology- and non-histology-driven therapy for soft-tissue sarcomas, including subtype-specific drug sensitivities |
| 24555529 | 2014 | Review | Expert Review of Anticancer Therapy | Emerging therapies for adult soft-tissue sarcoma |
| 24712007 | 2014 | Review | Magyar Onkologia | Medical treatment of soft-tissue sarcomas based on histological subtype |
| 28423517 | 2017 | Genomic/Translational | Oncotarget | Next-generation sequencing of extraskeletal myxoid chondrosarcoma, evaluating predictors of sunitinib benefit |
| 25884155 | 2015 | Trial protocol | BMC Cancer | REGOSARC trial protocol (regorafenib in advanced soft-tissue sarcoma); background context on TKI activity in sarcoma |
| 38717131 | 2024 | Case series | American Journal of Surgical Pathology | Clinicopathologic analysis of myxoid inflammatory myofibroblastic sarcoma (25 cases); background sarcoma-classification context, not sunitinib-specific |
New Zealand Market Information
Sunitinib currently holds no product authorizations in New Zealand (market status: Not Marketed, 0 licenses on record).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (multitargeted receptor tyrosine kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: Two Phase 2 trials and case-level literature show mechanistic plausibility and some clinical benefit for sunitinib in liposarcoma, but no liposarcoma-specific randomized trial exists, and response is subtype-dependent — evidence supports a defined research question rather than a Go/Hold decision at this time.
To proceed, the following is needed:
- TFDA/regulatory package insert data (blocking gap, DG001) to complete the S1 safety pre-screen
- Formal DrugBank mechanism-of-action data (DG002) to strengthen the mechanistic-link analysis
- A liposarcoma-subtype-stratified prospective or retrospective study to clarify which histological subtypes (e.g., dedifferentiated, myxoid/round-cell) respond
- Drug interaction and myelosuppression/emetogenicity data specific to New Zealand labeling, since the product is not currently marketed there
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.